Boustead IPO Client Soliton Added to the Russell 2000 and 3000 Indexes

Boustead Securities, LLC, IPO client Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a new and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), announced that the company was added to the Russell 2000® and 3000® Indexes, effective after the market close on Friday, June 28, 2019, as part of the Russell Indexes annual reconstitution.

FTSE Russell, a British index provider, makes available a comprehensive range of reliable and accurate indexes used by investors to measure and analyze global markets across asset classes, styles or strategies. The Russell U.S. Indexes have been widely accepted by institutional investors for their academic integrity and investor usability. Russell U.S. Indexes are part of FTSE Russell, a leading global index provider. FTSE Russell determines membership for its Russell U.S. Indexes primarily by objective, market-capitalization rankings and style attributes.

Membership in the Russell 3000® Index means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, and also includes the appropriate growth and value style indexes. For more information on the Russell Indexes go to the "Russell Reconstitution" section on the FTSE Russell website.

"We are thrilled to be included among the companies that comprise the Russell Indexes," said Lori Bisson, Soliton's Chief Financial Officer. "As the FTSE Russell seeks to benchmark the entire U.S. stockmarket, our inclusion in these indexes within just five months of our IPO is gratifying and reflection of the potential we believe investors see in Soliton's future."

Boustead Securities served as Sole Underwriter for Soliton’s $10,862,955 Reg A+ Initial Public Offering on Nasdaq on February 19, 2019. Boustead Securities acted as co-placement agent for Soliton’s $9.45 million private placement follow-on offering of its equity securities which closed on June 19, 2019.

This press release is not a solicitation or offer to buy or sell securities. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results.

About Soliton, Inc.

Soliton, Inc. is a pre-revenue stage medical device company with a proprietary platform technology licensed from MD Anderson. The Company’s first commercial product uses rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing this device to the market. For more information about the Company, please visit: http://www.soliton.com

About Boustead Securities, LLC

Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States and around the world, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com

Contact:

Dan McClory, Head of Equity Capital Markets

Boustead Securities, LLC Managing Director

E-mail: [email protected]

Phone: (949) 502 - 4408

About Boustead & Company Limited

Boustead & Company Limited is a diversified and comprehensive non-bank financial institution with offices in Los Angeles, New York, San Francisco, London and Beijing that is rapidly expanding in growth markets throughout the US and Asia.  Through its principals and fully-licensed subsidiaries Boustead & Company possesses rich experience and exceptional capabilities in capital markets deal execution and is dedicated to providing best-in-class one-stop financial services to clients.  Boustead’s comprehensive financial services platform consists of four operating units: Boustead Securities, LLC, a US-based FINRA Broker/Dealer and middle-market investment bank; Sutter Securities Group, Inc. which owns three FINRA-regulated entities: Sutter Securities, Inc., Sutter Securities Clearing, LLC, and FlashFunders Funding Portal, LLC, along with fund manager Sutter Capital Management, Inc.; Sutter Capital Partners, LLC a California Registered Investment Advisor; and Boustead Capital Markets, LLP a London-based FCA-regulated company.

About Sutter Securities Group, Inc.

Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC and Sutter Securities Inc., both FINRA member broker-dealers; Sutter Capital Partners, LLC, a California Registered Investment Advisor, Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. SSG, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws.   SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.SutterSecurities.com and www.flashfunders.com